Priorities
Psychedelic Medicine
After a 50 year freeze on psychedelics research, a new psychedelics renaissance is unfolding. As the field rapidly advances, we must continue to ask ethical questions about the safety, accessibility, legality, and public perceptions surrounding these drugs.
The ScattergoodEthics Program examines novel ethical issues in clinical research and treatment with psychedelic drugs such as informed consent, psychedelic professionalism, the inclusion of marginalized populations, and off-label use and marketing.
Latest Work
Hastings Center Report
- Daniel Rosenbaum
- Crystal Hare
- Emma Hapke
- Yarissa Herman
- Susan Abbey
- Dominic Sisti, PhD
- Daniel Buchman
JAMA Network Open
Read this entryPerspectives in Biology and Medicine
Read this entryNature Medicine
Read this entryPerspectives in Biology and Medicine
Read this entry